Indianapolis-based Prevounce designed OX1-LTE to provide numerous advantages over other pulse oximeters, according to a news release. It aids patients in RPM programs for chronic respiratory conditions, such as chronic obstructive pulmonary disease (COPD) or asthma, and a variety of other scenarios. Those scenarios could include COVID-19 or patients undergoing treatments that require heart monitoring.
OX-1-LTE can roam on multiple cellular networks while delivering reliable connectivity. It enables consistent, secure data transmission to patient care teams, even in areas with a weak signal. Prevounce said the cost-effectiveness of the device makes it easier for organizations to invest in their growing RPM programs.
The FDA-cleared device delivers blood oxygen saturation (SpO2) readings accurate to within 2 percent and pulse rates accurate to within 2 beats per minute (bpm). It features a bright, clear OLED screen and ergonomic design for easy reading and operating. The system requires no configuration and its high-quality materials reduce the likelihood of damage and device failure.
Prevounce offers the pulse oximeter with its remote care management platform. It also integrates with third-party health software via the Pylo cloud API.
“We’re excited to add OX1-LTE to the family of Pylo devices available for use in RPM programs,” said Daniel Tashnek, founder and CEO of Prevounce. “The OX1-LTE couldn’t be simpler for patients to use, which will boost RPM program engagement and participation while reducing the clinician and technical support work required to scale remote monitoring programs.”
